Biotech Stocks Are Soaring In Pre-Market Update at Mid Morning

NASDAQ Up 39 to 5031  Healthcare Stocks Continue To Lead

Biogen Idec (BIIB) Up 10% On Alzheimer Disease Phase 1 Data

Encouraging Phase I data on aducanumab with 166 patients shows acceptable safety and amyloid plaque reduction prompts Company to skip early stage study and move on to Phase 3.

Update at Mid-morning

Pin It on Pinterest